Yet another alliance has been formed to help transform healthcare. This time 20 major employers, who represent 4 million employees and family members, have come together to improve how healthcare benefits are purchased.
Yet another alliance has been formed to help transform healthcare. This time 20 major employers, who represent 4 million employees and family members, have come together to improve how healthcare benefits are purchased.
The alliance will focus on reforms that can reduce redundancies and waste in the supply chain.
“The current system is unsustainable and it costs our employees too much,” Kevin Cox, the chief human resources officer of American Express, said in a statement. “Even the most successful companies won’t be able to afford the rising costs of health care in the not-too-distant future.”
The newly formed Health Transformation Alliance (HTA) will play a part of each participating company’s health strategy with the aim to increase innovation, better analyze data, and better leverage how corporations obtain coverage for workers.
In 2017, HTA will launch a pilot to help employees obtain more affordable prescription medications with other initiatives planned to begin in 2018 or later.
“Our priority in this coalition is supporting positive health outcomes for our strongest asset—our employees,” said Kim Hauer, the chief human resources officer at Caterpillar. “Health care benefits are too important to our people for us to sit on the sidelines; the status quo needs to change, and we have to be part of the solution. We are creating a better way of getting workers what they want and need.”
There are 4 main areas of focus of HTA:
“We have considerable work to do, and we expect this will take years to fully implement,” said Bill Allen, the CHRO of Macy’s Inc. “This is a major undertaking for each of us, but if we don’t do it now, the growth in health care costs will overwhelm all of us. We are proud to be pioneers who seek to transform and improve the way health care benefits are provided for millions of working Americans.”
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
March 21st 2025Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen